CN105593238B - 使用微生物转谷氨酰胺酶进行赖氨酸特异性化学酶法蛋白质修饰 - Google Patents

使用微生物转谷氨酰胺酶进行赖氨酸特异性化学酶法蛋白质修饰 Download PDF

Info

Publication number
CN105593238B
CN105593238B CN201480046805.8A CN201480046805A CN105593238B CN 105593238 B CN105593238 B CN 105593238B CN 201480046805 A CN201480046805 A CN 201480046805A CN 105593238 B CN105593238 B CN 105593238B
Authority
CN
China
Prior art keywords
certain embodiments
protein
acid
group
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480046805.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN105593238A (zh
Inventor
艾梅·尤塞拉
扎卡里·鲁滨逊
珍妮弗·科布
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN105593238A publication Critical patent/CN105593238A/zh
Application granted granted Critical
Publication of CN105593238B publication Critical patent/CN105593238B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D229/00—Heterocyclic compounds containing rings of less than five members having two nitrogen atoms as the only ring hetero atoms
    • C07D229/02—Heterocyclic compounds containing rings of less than five members having two nitrogen atoms as the only ring hetero atoms containing three-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/08—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13—Labelling of peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/24—All rings being cycloaliphatic the ring system containing nine carbon atoms, e.g. perhydroindane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Gastroenterology & Hepatology (AREA)
CN201480046805.8A 2013-07-11 2014-07-11 使用微生物转谷氨酰胺酶进行赖氨酸特异性化学酶法蛋白质修饰 Active CN105593238B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361845273P 2013-07-11 2013-07-11
US61/845,273 2013-07-11
US201462016044P 2014-06-23 2014-06-23
US62/016,044 2014-06-23
PCT/US2014/046409 WO2015006728A2 (en) 2013-07-11 2014-07-11 Site-specific chemoenzymatic protein modifications

Publications (2)

Publication Number Publication Date
CN105593238A CN105593238A (zh) 2016-05-18
CN105593238B true CN105593238B (zh) 2020-09-08

Family

ID=51298955

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480046805.8A Active CN105593238B (zh) 2013-07-11 2014-07-11 使用微生物转谷氨酰胺酶进行赖氨酸特异性化学酶法蛋白质修饰

Country Status (12)

Country Link
US (4) US9359400B2 (enExample)
EP (2) EP3019515B1 (enExample)
JP (1) JP6739333B2 (enExample)
KR (1) KR20160040556A (enExample)
CN (1) CN105593238B (enExample)
AU (1) AU2014286990A1 (enExample)
BR (1) BR112016000585A2 (enExample)
CA (1) CA2918076A1 (enExample)
EA (1) EA201690205A1 (enExample)
ES (1) ES2756526T3 (enExample)
MX (1) MX2016000393A (enExample)
WO (1) WO2015006728A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015006728A2 (en) * 2013-07-11 2015-01-15 Usera Aimee Site-specific chemoenzymatic protein modifications
US10588980B2 (en) * 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
CA3008645A1 (en) * 2015-12-18 2017-06-22 Eisai R&D Management Co., Ltd. C-terminal lysine conjugated immunoglobulins
EP3436061A4 (en) 2016-03-31 2019-12-04 Liffey Biotech Limited Saccharide-polypeptide-conjugate compositions and methods of use thereof
UA126799C2 (uk) 2016-06-10 2023-02-08 ЕЙСАЙ Ар ЕНД Ді МЕНЕДЖМЕНТ КО., ЛТД. Кон'югований імуноглобулін
AU2017321863B2 (en) 2016-09-02 2024-07-11 Sanofi Pasteur, Inc. Neisseria meningitidis vaccine
WO2018126229A2 (en) 2016-12-30 2018-07-05 Sutrovax, Inc. Polypeptide-antigen conjugates with non-natural amino acids
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
US12257295B2 (en) 2017-10-04 2025-03-25 Pogona, LLC Saccharide-polypeptide conjugate compositions and methods of use thereof
AU2020212055B2 (en) * 2019-01-25 2025-10-02 Avedro, Inc. Bis(diazirine) derivatives as photo-crossslinker for treating corneal ectatic disorders
WO2023244963A2 (en) * 2022-06-16 2023-12-21 The General Hospital Corporation Bicyclononyne reagents for cell imaging
WO2025020905A1 (zh) * 2023-07-26 2025-01-30 菲鹏生物股份有限公司 抗体和抗体缀合物及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543397A (en) * 1990-07-12 1996-08-06 Degussa Aktiengesellschaft New N-acyl dipeptides and their use
EP0815833A3 (en) * 1996-06-24 1998-05-27 Givaudan-Roure (International) S.A. Malodour preventing agents
WO2010002042A1 (ja) * 2008-07-04 2010-01-07 国立大学法人 九州大学 タンパク質ラベル化用酵素基質

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPH0665280B2 (ja) 1987-03-04 1994-08-24 味の素株式会社 タンパクゲル化剤及びそれを用いるタンパクのゲル化方法
JP2849773B2 (ja) 1990-08-27 1999-01-27 天野製薬株式会社 ストレプトミセス属由来のトランスグルタミナーゼの製造法
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
US5425946A (en) 1992-08-31 1995-06-20 North American Vaccine, Inc. Vaccines against group C Neisseria meningitidis
EP0658118B1 (en) 1992-08-31 2002-01-23 Baxter Healthcare S.A. Vaccines against group c neisseria meningitidis
US5508191A (en) 1993-07-05 1996-04-16 Takeda Chemical Industries, Ltd. Mutant strains of agrobacterium for producing β-1,3-glucan
NZ291414A (en) 1994-08-26 1998-05-27 Novo Nordisk As Microbial transglutaminases and methods of production using fungi and dna constructs
US6010871A (en) 1994-09-29 2000-01-04 Ajinomoto Co., Inc. Modification of peptide and protein
NZ298746A (en) 1995-01-19 1998-07-28 Novo Nordisk As Transglutaminases from oomcyetes
JP3669390B2 (ja) 1995-02-09 2005-07-06 味の素株式会社 バチルス属細菌由来のトランスグルタミナーゼ
US6284884B1 (en) 1995-06-07 2001-09-04 North American Vaccine, Inc. Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof
EP0950665A4 (en) 1996-09-26 2004-05-06 Ajinomoto Kk PHYSIOLOGICALLY ACTIVE MODIFIED PROTEINS AND DRUG COMPOSITIONS CONTAINING THEM
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
EP1054998A1 (en) 1998-01-20 2000-11-29 Pericor Science, Inc. Transglutaminase linkage of agents to tissue
US6958148B1 (en) 1998-01-20 2005-10-25 Pericor Science, Inc. Linkage of agents to body tissue using microparticles and transglutaminase
US6919076B1 (en) 1998-01-20 2005-07-19 Pericor Science, Inc. Conjugates of agents and transglutaminase substrate linking molecules
US6936258B1 (en) 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
EP1355673B1 (en) 2001-01-23 2012-05-30 Sanofi Pasteur Inc. Multivalent meningococcal polysaccharide-protein conjugate vaccine
US7605175B2 (en) 2001-03-02 2009-10-20 Gpc Biotech Ag Inhibitors of cyclin-dependent kinases, compositions and uses related thereto
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
JP2003199569A (ja) 2001-12-17 2003-07-15 Food Industry Research & Development Inst ストレプトベルティシリウム・ラダカヌムのトランスグルタミナーゼ遺伝子及び該遺伝子によってコードされるトランスグルタミナーゼ
BR0308768A (pt) 2002-03-26 2005-02-15 Chiron Srl Sacarìdeos modificados possuindo estabilidade melhorada em água
GB0211118D0 (en) 2002-05-15 2002-06-26 Polonelli Luciano Vaccines
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
KR20070052747A (ko) 2004-09-10 2007-05-22 도레이 가부시끼가이샤 의약품제제
MX2007005202A (es) 2004-11-01 2007-07-09 Brigham & Womens Hospital Polisacaridos de estreptococo modificados y usos de los mismos.
GB0502096D0 (en) 2005-02-01 2005-03-09 Chiron Srl Purification of streptococcal capsular polysaccharide
US20100197573A1 (en) * 2005-06-15 2010-08-05 Novo Nordisk Health Care Ag Transglutaminase Mediated Conjugation of Growth Hormone
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
CN101809032A (zh) * 2007-08-24 2010-08-18 诺沃-诺迪斯克有限公司 用于选择性修饰蛋白质的方法
US8426179B2 (en) * 2007-08-30 2013-04-23 Northwestern University Synthetic peptide and peptide conjugates and related tissue coupling methods via transglutaminase enzyme
DE102007044296A1 (de) * 2007-09-17 2009-03-19 Hans-Lothar Prof. Dr. Fuchsbauer Strukturmodulator von Proteinen
US8137925B2 (en) * 2007-11-09 2012-03-20 Massachusetts Institute Of Technology Methods and compositions for protein labeling using lipoic acid ligases
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
WO2010102886A1 (en) * 2009-02-19 2010-09-16 Novo Nordisk A/S Modification of factor viii
FR2947269B1 (fr) 2009-06-29 2013-01-18 Sanofi Aventis Nouveaux composes anticancereux
US8853151B2 (en) 2009-06-30 2014-10-07 The Regents Of The University Of Michigan Pro-drug complexes and related methods of use
US20110020837A1 (en) 2009-07-07 2011-01-27 Universiteit Utrecht Holding B.V. Method for isolating or identifying a target protein interacting with a lipid in a cell
CA2785410A1 (en) 2009-12-23 2011-06-30 Carlos F. Barbas, Iii Tyrosine bioconjugation through aqueous ene-like reactions
EP2563753B9 (en) 2010-04-27 2016-07-06 SynAffix B.V. Fused cyclooctyne compounds and their use in metal-free click reactions
EP2591354B1 (en) 2010-07-07 2016-09-07 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
US20130178609A1 (en) 2010-07-09 2013-07-11 Centre National De La Recherche Scientifique - Cnrs Modular construction of lipophospholipids
CN103298949A (zh) 2010-10-29 2013-09-11 生命科技公司 生物素衍生物
WO2012059882A2 (en) 2010-11-05 2012-05-10 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
WO2012078559A2 (en) 2010-12-07 2012-06-14 Yale University Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same
CN103370063A (zh) 2010-12-13 2013-10-23 免疫医疗公司 用于改善蛋白质、肽和其他分子的f-18标记的方法和组合物
WO2012142659A1 (en) 2011-04-19 2012-10-26 Baker Idi Heart And Diabetes Institute Holdings Limited Site-selective modification of proteins
FR2981352B1 (fr) * 2011-10-17 2015-07-03 Centre Nat Rech Scient Procede de synthese de proteines
WO2013078564A2 (en) * 2011-12-01 2013-06-06 Angiochem Inc. Targeted lysosomal enzyme compounds
JP5509440B2 (ja) * 2012-06-22 2014-06-04 国立大学法人九州大学 タンパク質−核酸複合体の製造方法および標的物の検出方法
WO2014202775A1 (en) * 2013-06-21 2014-12-24 Innate Pharma Enzymatic conjugation of polypeptides
WO2015006728A2 (en) * 2013-07-11 2015-01-15 Usera Aimee Site-specific chemoenzymatic protein modifications

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543397A (en) * 1990-07-12 1996-08-06 Degussa Aktiengesellschaft New N-acyl dipeptides and their use
EP0815833A3 (en) * 1996-06-24 1998-05-27 Givaudan-Roure (International) S.A. Malodour preventing agents
WO2010002042A1 (ja) * 2008-07-04 2010-01-07 国立大学法人 九州大学 タンパク質ラベル化用酵素基質

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Fluorescent substrates for covalent protein labeling catalyzed by microbial transglutaminase;N Kamiya;《Org. Biomol. Chem》;20090101;第7卷(第17期);全文 *
Langmuir monolayers of diacyl glycerol amino acid-based surfactants. Effect of the substitution pattern of the glycerol backbone;R Albalat;《Langmuir》;20031201;第19卷(第26期);全文 *
Modification of Different IgG1 Antibodies via Glutamine and Lysine using Bacterial and Human Tissue Transglutaminase;Thomas L. Mindt等;《Bioconjugate Chem》;20080101;第19卷(第1期);第271页摘要和第274页表1中化合物2 *
site-specific modification of proteins mediated by transglutaminase;Abhijeet Satwekar;《NATURE PRECEDINGS》;20110606;全文 *

Also Published As

Publication number Publication date
WO2015006728A3 (en) 2015-03-12
US10975120B2 (en) 2021-04-13
US20160237116A1 (en) 2016-08-18
AU2014286990A1 (en) 2016-02-11
US20220089639A1 (en) 2022-03-24
US20190300570A1 (en) 2019-10-03
EP3019515A2 (en) 2016-05-18
EA201690205A1 (ru) 2016-12-30
WO2015006728A2 (en) 2015-01-15
MX2016000393A (es) 2016-10-26
US9359400B2 (en) 2016-06-07
KR20160040556A (ko) 2016-04-14
BR112016000585A2 (pt) 2018-03-20
CA2918076A1 (en) 2015-01-15
JP2016526574A (ja) 2016-09-05
CN105593238A (zh) 2016-05-18
JP6739333B2 (ja) 2020-08-12
US20150017192A1 (en) 2015-01-15
EP3019515B1 (en) 2019-08-21
EP3613755A1 (en) 2020-02-26
ES2756526T3 (es) 2020-04-27

Similar Documents

Publication Publication Date Title
CN105593238B (zh) 使用微生物转谷氨酰胺酶进行赖氨酸特异性化学酶法蛋白质修饰
AU698944B2 (en) Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations
CN103349780B (zh) 链球菌荚膜糖的偶联
CN104080479B (zh) 包括spr0096和spr2021抗原的运载体分子
JP2022058911A (ja) 非血液凝固タンパク質の糖ポリシアル酸化
US7700551B2 (en) Hydrolysable polymeric FMOC-linker
JP7100031B2 (ja) 免疫原性コンジュゲート及びその使用
US7812006B2 (en) Conjugates obtained by reductive amination of the pneumococcus serotype 5 capsular polysaccharide
BR112020018974A2 (pt) Glicoconjugados de precisão como ferramentas terapêuticas
WO2020010016A1 (en) Self-adjuvanted immunogenic conjugates
KR101266552B1 (ko) 그룹 ｙ 수막염균에 대한 백신 및 그의 수막염균성 조합
US11097000B2 (en) Klebsiella pneumoniae capsule polysaccharide vaccines
EP3491000B1 (en) Stable hydrolysis-resistant synthetic polyribosylribitolphosphate derivatives as vaccines against haemophilus influenzae type b
US10772946B2 (en) Immunogenic compositions against S. aureus
HK40008295B (en) Stable hydrolysis-resistant synthetic polyribosylribitolphosphate derivatives as vaccines against haemophilus influenzae type b
HK40008295A (en) Stable hydrolysis-resistant synthetic polyribosylribitolphosphate derivatives as vaccines against haemophilus influenzae type b
WO2009033269A1 (en) Novel polysaccharide immunogens from alloiococcus otitidis and synthesis of a glycoconjugate vaccine thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant